Description
The article is a reply to Dunning, J. Potential adverse effects of negative publicity surrounding antivirals for influenza. BMJ2014;348:g3015.Citation
Doshi, P. & Jefferson, T. (2014). Authors' reply to Dunning. BMJ 2014;348:g3018. DOI: https://doi.org/10.1136/bmj.g3018Keyword
neuraminidase inhibitorsnon-pandemic influenza
Systematic reviews (Medical research)
Influenza, Human
Identifier to cite or link to this item
http://hdl.handle.net/10713/6587ae974a485f413a2113503eed53cd6c53
10.1136/bmj.g3018
Scopus Count
Collections
Related articles
- Neuraminidase inhibitors for influenza complications--Authors' reply.
- Authors: Nguyen-Van-Tam JS, Openshaw PJ, Nicholson KG
- Issue date: 2014 Oct 4
- Oseltamivir for influenza - Authors' reply.
- Authors: Monto AS, Dobson J, Pocock S, Whitley RJ
- Issue date: 2016 Jan 9
- Oseltamivir for influenza - Authors' reply.
- Authors: Monto AS, Dobson J, Pocock S, Whitley RJ
- Issue date: 2015 Sep 19
- Authors' reply to Mark Jones's critique of the study by Muthuri and colleagues reported in The BMJ.
- Authors: Myles PR, Leonardi-Bee J, PRIDE Research Consortium Investigators
- Issue date: 2014 Apr 30
- Authors' reply to Mark Jones's second critique of the study by Muthuri and colleagues reported in The BMJ.
- Authors: Myles PR, Leonardi-Bee J, PRIDE research consortium investigators
- Issue date: 2014 Apr 30